Oncology

Latest News

Highlights From ASCO 2024
ICYMI: Highlights From ASCO 2024

December 21st 2024

Top coverage from the 2024 American Society of Clinical Oncology (ASCO) annual meeting included research topics in non-small cell lung cancer (NSCLC), multiple myeloma, metastatic colorectal cancer (mCRC), and more.

chemotherapy | Image credit: Penn Medicine
The High Cost of Shortages of Low-Cost Chemotherapy

December 19th 2024

Leukemia diagnosis | Image credit: Vitalii Vodolazskyi - stock.adobe.com
Real-World Treatment Sequences and Cost Analysis of cBTKis in CLL

December 17th 2024

FDA approved stamp in black with a red ribbon across it | Image credit: BHM - stock.adobe.com
Cosibelimab Approved for Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

December 16th 2024

Highlights From COA 2024
ICYMI: Highlights From COA 2024

December 14th 2024

Join this panel as they discuss treatment for metastatic NSCLC patients without driver mutations.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

Jessa Dunivan Explains How the Role of Care Coordinator Has Been Influenced by Value-Based Care
March 15th 2019

Jessa Dunivan Explains How the Role of Care Coordinator Has Been Influenced by Value-Based Care

Care coordinators are a support system for the clinical and the clerical teams to make sure that nothing falls through the cracks, explained Jessa Dunivan, patient services manager, Northwest Medical Specialties.
Dr Lawrence N. Shulman Reveals Similarities in Cancer Care Challenges Between the Rural US and Rwanda
March 14th 2019

Dr Lawrence N. Shulman Reveals Similarities in Cancer Care Challenges Between the Rural US and Rwanda

There are similarities between the challenges of accessing good cancer care in rural areas of the United States and Rwanda, such as poverty, transportation, and lack of routine care, said Lawrence N. Shulman, MD, director of the Center for Global Cancer Medicine at the Abramson Cancer Center, and professor of Medicine at the Hospital of the University of Pennsylvania.
FDA Expands Patient Inclusion Criteria for Cancer Clinical Trials
March 14th 2019

FDA Expands Patient Inclusion Criteria for Cancer Clinical Trials

Samantha DiGrande
In an effort to increase patient accrual, broaden patients’ access to cancer clinical trials, and lead to trial results that better represent treatment effects in the real world, the FDA published 4 draft guidances and 1 final guidance to promote the inclusion of pediatric patients and patients with comorbidities that can occur alongside cancer.
Abra Kelson: Working Through Stigmas Associated With the Social Worker Position
March 13th 2019

Abra Kelson: Working Through Stigmas Associated With the Social Worker Position

Sometimes, patients may misunderstand the role of the social worker as part of the care team, but ultimately, they end up really being appreciative of the services, said Abra Kelson, MSW, LSWA-IC, medical social work supervisor, Northwest Medical Specialties.
FDA Approves Atezolizumab Combination for Triple-Negative Breast Cancer
March 11th 2019

FDA Approves Atezolizumab Combination for Triple-Negative Breast Cancer

Jaime Rosenberg
The approval is based off of progression-free survival data from the IMpassion130 study and represents the first approved immunotherapy regimen for breast cancer.
Dr Janice Mehnert on Treatment Developments, Payer Coverage for Immunotherapy
March 9th 2019

Dr Janice Mehnert on Treatment Developments, Payer Coverage for Immunotherapy

I think we’re in a bit of a lull for exciting new therapy developments, likely because the development of the checkpoint inhibitors has just been so extraordinary revolutionary, explained Janice Mehnert, MD, Head of the Phase I Developmental Therapeutics Program at Rutgers Cancer Institute of New Jersey, and the Head of the Melanoma Research Team.
Addressing Disparities in End-of-Life Care in Blood Cancers
March 8th 2019

Addressing Disparities in End-of-Life Care in Blood Cancers

Laura Joszt, MA
While use of palliative care at the end of life has increased, disparities remain, and not all patients who are terminally ill with blood cancers are having discussions about their goals of care at the end of life.
Site Logo
March 7th 2019

Cost Differential of Immuno-Oncology Therapy Delivered at Community Versus Hospital Clinics

Lucio Gordan, MD Marlo Blazer, PharmD, BCOP Vishal Saundankar, MS Denise Kazzaz Susan Weidner, MS Michael Eaddy, PharmD, PhD
Administration of immuno-oncology therapy for cancer diagnoses in the community clinic setting is associated with lower costs compared with administration in a hospital-based clinic setting.
Detecting MRD During and After Hematopoietic Stem Cell Transplantation
March 5th 2019

Detecting MRD During and After Hematopoietic Stem Cell Transplantation

Laura Joszt, MA
Two abstracts presented at the Transplantation and Cellular Therapy Meetings analyzed the detection of minimal residual disease during and after hematopoietic stem cell transplantation.
Patients With RRMM Are Undertreated With Carfilzomib in the Real World, Study Finds
March 2nd 2019

Patients With RRMM Are Undertreated With Carfilzomib in the Real World, Study Finds

Laura Joszt, MA
Since carfilzomib was approved at a 27 mg/m2 twice-weekly dose, it has since been optimized at 56 mg/m2 twice-weekly and a recent study found benefits of a 70 mg/m2 once-weekly dose. However, most patients are still treated with the original approval dosage, suggesting they might be undertreated.
Biologic Age Associated With Breast Cancer Risk
March 2nd 2019

Biologic Age Associated With Breast Cancer Risk

Samantha DiGrande
Scientists at the National Institutes of Health have recently found that biologic age, or a DNA-based estimate of a person’s age, is associated with future development of breast cancer.
Improving Patient-Reported Measurement in Oncology Value-Based Care
March 1st 2019

Improving Patient-Reported Measurement in Oncology Value-Based Care

Allison Inserro
How to improve patient-reported measurement in oncology valued-based care is the focus of a new report from The National Pharmaceutical Council and Discern Health.
What We're Reading: Flu Shot During Pregnancy; Liquid Biopsy for NSCLC; Physician-Generated Revenue
February 28th 2019

What We're Reading: Flu Shot During Pregnancy; Liquid Biopsy for NSCLC; Physician-Generated Revenue

AJMC Staff
Researchers have confirmed that there is no link between flu shots and miscarriages; a liquid biopsy is as effective as tissue-based testing for identifying treatment for lung cancer; and physicians generate an average of $2 million a year for hospitals.
Site Logo
February 27th 2019

Mergers, New Locations for Care, and the Oncologist

Bruce Feinberg, DO, vice president and chief medical officer for Cardinal Health Specialty Solutions, recently chaired a discussion centered on the flurry of megamergers in healthcare: Walmart and Humana, Aetna and CVS, Cigna and Express Scripts, and Amazon and PillPack.
Improving Oncology Practices With Value-Based Care
February 27th 2019

Improving Oncology Practices With Value-Based Care

On March 7, The American Journal of Managed Care® will host its latest Institute for Value-Based Medicine in Dallas, Texas, with the Advancing Quality Oncology Care in the Evolving Value-Based Care Landscape meeting.
Using NGS to Assess Minimal Residual Disease Better Predicts Outcomes in AML
February 26th 2019

Using NGS to Assess Minimal Residual Disease Better Predicts Outcomes in AML

Laura Joszt, MA
A high proportion of patients with acute myeloid leukemia (AML) who achieve a negative minimal residual disease (MRD) status still relapse, indicating a more sensitive method of detecting MRD is needed.
Site Logo
February 26th 2019

Therapeutics

Christina Mattina Mary Caffrey
Therapeutic updates from Patient-Centered Oncology Care® 2018.
Site Logo
February 26th 2019

Reporting and Design

Mary Caffrey Jaime Rosenberg
Updates on reporting otucomes and pathway design from Patient-Centered Oncology Care®.
Site Logo
February 25th 2019

Looking Ahead

Christina Mattina Mary Caffrey
Various stakeholders discuss the future of oncology care at the Patient-Centered Oncology Care® meeting. Editor’s Note: After this issue went to press, Wes Hall passed away February 20, 2019, after living more than 5 years with stage IV stomach cancer. He was active in the Community Oncology Alliance Patient Advocacy Network and supported participation in clinical trials.
Site Logo
February 25th 2019

Keynote Speaker: AMA's McAneny Calls for Real-time Oncology Payment Model Led by Physicians

Mary Caffrey
The major alternative payment model put forth by Medicare, the Oncology Care Model, doesn’t tell practices how they are doing until after the fact. This puts practices at risk for things beyond their control, said Barbara McAneny, MD, a New Mexico oncologist/hematologist who is the current president of the American Medical Association (AMA).
Podcast: This Week in Managed Care—CAR T Therapy Coverage and Other Health News
February 24th 2019

Podcast: This Week in Managed Care—CAR T Therapy Coverage and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
PET Scans Could Identify Patients With Breast Cancer Who May Be Able to Avoid Chemotherapy
February 22nd 2019

PET Scans Could Identify Patients With Breast Cancer Who May Be Able to Avoid Chemotherapy

Laura Joszt, MA
Researchers have used positron emission tomography scans to identify which patients with a type of human epidermal growth factor receptor 2–positive breast cancer might benefit most from targeted agents alone and can be spared chemotherapy.
Pursuing Eradication of Cervical Cancer Through Preventive Interventions
February 20th 2019

Pursuing Eradication of Cervical Cancer Through Preventive Interventions

Wallace Stephens
The majority of countries could see an end to cervical cancer as a public health problem by 2060, according to a new study in The Lancet Oncology.
Breast Surgeons Seek Genetic Testing for All Patients With Breast Cancer
February 19th 2019

Breast Surgeons Seek Genetic Testing for All Patients With Breast Cancer

Mary Caffrey
The update follows a study published in November that found almost no difference in the frequency of mutations between patients with breast cancer who met National Comprehensive Cancer Network guidelines and those who didn't.
Site Logo
February 19th 2019

Humanistic and Economic Burden of Hepatocellular Carcinoma: Systematic Literature Review

Christine G. Kohn, PharmD Prianka Singh, PharmD, MPH Beata Korytowsky, MA Jonathan T. Caranfa, PharmD Jeffrey D. Miller, MS Bruce E. Sill, PharmD, MS Alexander C. Marshall, PharmD, MPH Neehar D. Parikh, MD, MS
Worldwide, more than half a million new cases of hepatocellular carcinoma (HCC) are diagnosed annually. The incidence of HCC in the United States is rising with an estimated 31,000 new cases in 2018. Disease prognosis remains poor, with a 5-year survival rate across all disease stages estimated between 10%-20%, and 3% for those diagnosed with distant disease. Although morbidity is significant, especially among patients with advanced-stage disease, limited information exists on the humanistic and economic burden of HCC.
Podcast: This Week in Managed Care—Contraceptive Demand and Other Health News
February 17th 2019

Podcast: This Week in Managed Care—Contraceptive Demand and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
Dr Thomas Martin Outlines How MRD Testing Is Being Used
February 16th 2019

Dr Thomas Martin Outlines How MRD Testing Is Being Used

Currently, minimal residual disease testing is being used for prognostication not for treatment decisions, explained Thomas G. Martin, MD, clinical professor of medicine, Adult Leukemia and Bone Marrow Transplantation Program, associate director, Myeloma Program, University of California, San Francisco (UCSF); co-leader, Hematopoietic Malignancies Program, Helen Diller Family Comprehensive Cancer Center.
Site Logo
February 15th 2019

AJMCtv® Interviews, February 2019

AJMC®TV interviews let you catch up on what’s new and important about changes in healthcare, with insights from key decision makers—from the clinician, to the health plan leader, to the regulator. When every minute in your day matters, AJMC®TV interviews keep you informed. Access the video clips at ajmc.com/interviews.
This Week in Managed Care: February 15, 2019
February 15th 2019

This Week in Managed Care: February 15, 2019

This week, the top managed care news included increased demand for long-acting contraception since President Trump took office; a payer decision on an insulin pump alarmed diabetes advocates; and despite being involved in cancer treatment decisions, many primary care providers don't feel prepared to do so.
Patients With Relapsed/Refractory MM More Likely to Have Sustained MRD on Daratumumab
February 15th 2019

Patients With Relapsed/Refractory MM More Likely to Have Sustained MRD on Daratumumab

Laura Joszt, MA
Minimal residual disease (MRD) is a strong prognosticator of cancer outcomes, and recent research found that patients with relapsed/refractory multiple myeloma (MM) are more likely to achieve MRD on daratumumab than on a standard of care alone.
<1
...
252627282930313233
...
181>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo